Literature DB >> 35965922

How we dealt with the double whammy! Acute pulmonary embolism with abdominal aortic clot and renal infarcts.

Sherif Roman1, Abanoub Rushdy2, Hamdallah Ashkar1, Christopher Millet1, Erinie Mekheal1, Sewar Abuarqob1, Hartaj Virk2.   

Abstract

Pulmonary embolism (PE) is the third most common cause of cardiovascular mortality in the United States, and the submassive PE accounts for 20%-25% of all acute PE. In the last decade, endovascular therapy with catheter-directed thrombolysis (CDT) intervention has shown great success in the treatment of submassive PE. There is limited data regarding using these devices to treat patients with concomitant abdominal aortic and renal vessel clots. Herein, we present a case of a 23-year-old male who presented with submassive PE associated with abdominal aortic thrombosis and renal infarcts. The patient was successfully treated with CDT with complete resolution of pulmonary and bilateral renal artery clots. Published by Elsevier Inc. on behalf of University of Washington.

Entities:  

Keywords:  Catheter-directed therapy; Mechanical thrombectomy; Pulmonary embolism; Renal artery thrombosis

Year:  2022        PMID: 35965922      PMCID: PMC9372741          DOI: 10.1016/j.radcr.2022.07.054

Source DB:  PubMed          Journal:  Radiol Case Rep        ISSN: 1930-0433


Introduction

Pulmonary embolism (PE) is the third leading cause of cardiovascular mortality in the United States [1]. It has variable clinical presentations and can be a mild, moderate, and sometimes fatal disease [2]. Pulmonary embolisms are classified into low risk, sub-massive, and massive groups based on hemodynamic stability, cardiac biomarkers and right ventricular (RV) strain [3]. Catheter-directed thrombolysis (CDT) is one of the latest treatment options, and it is thought to be safer than systemic thrombolysis with better efficacy than anticoagulation alone. There is limited data regarding using these devices in the treatment of renal vessel clots. In this report, we present the case of a young male who presented with submassive PE along with abdominal aortic thrombosis and renal infarcts, and was successfully treated with CDT.

Case presentation

A 23-year-old male with a past medical history of morbid obesity and obstructive sleep apnea presented to our facility with sudden onset of shortness of breath that started earlier on the day of presentation. The patient also reported that he had 2 syncopal events since the last night associated with brief periods of dyspnea before losing consciousness. He denies any chest pain, fever, history of smoking, malignancies, recent surgeries or travels. Initial vital signs showed a temperature of 36.4°C, heart rate of 118/min, blood pressure 110/66, respiratory rate of 20/min, and hypoxia with SpO2 of 85% on room air. The patient was subsequently placed on a 4L nasal cannula with improvement in SpO2 to 98%. Physical exam revealed fair air entry to the lungs bilaterally with no rales or rhonchi. He was also noted to have right lower limb pitting edema. Electrocardiogram (EKG) showed sinus tachycardia without signs of right heart strain, and troponin was 298. CT angiography of chest/abdomen revealed extensive bilateral pulmonary emboli with high clot burden and findings suggesting right heart strain in addition to thrombus seen within the abdominal aorta extending into the renal arteries bilaterally with bilateral renal infarcts (Fig. 1).
Fig. 1.

CT angiography of chest/abdomen showing extensive bilateral pulmonary emboli with high clot burden (A) and findings suggesting right heart strain with increased RV/LV ratio (B) in addition to thrombus seen within the abdominal aorta extending into the renal arteries bilaterally (C) with bilateral renal infarcts (D).

CT angiography of chest/abdomen showing extensive bilateral pulmonary emboli with high clot burden (A) and findings suggesting right heart strain with increased RV/LV ratio (B) in addition to thrombus seen within the abdominal aorta extending into the renal arteries bilaterally (C) with bilateral renal infarcts (D). As the patient was hemodynamically stable with elevated cardiac biomarkers and CT findings suggesting RV strain, he meets the diagnostic criteria for high-risk submassive PE. Treatment options were discussed with the patient, including systemic thrombolytic therapy vs catheter-directed therapy. Given the significant risks of systemic thrombolytic therapy, including intracranial hemorrhage, the catheter-directed approach was pursued. On the other hand, the presence of bilateral renal thrombi was another challenge, so we had 2 suggestions: either administer localized tissue plasminogen activator (tPA) for pulmonary embolism and then reevaluate the renal arteries thrombi later or perform an urgent renal artery intervention. Because the kidneys' perfusion was still preserved, the decision was made to perform pulmonary thrombolysis and then repeat the angiogram the following day and decide about the renal intervention. We also had 2 suggestions if the renal clots were not dissolved: either administering localized tPA for the renal clots or using an extraction device for aspiration. Directed thrombolytic infusion with ultrasonic enhancement using the EKOS catheter was performed for the pulmonary embolism. A total of 24 mg tPA was used: 2 mg per catheter per hour for 6 hours and then 1 mg per hour per catheter for another 12 hours. Fortunately, the repeat angiogram showed resolution of all the thrombi, including renal thrombi, with no intervention needed, and a significant improvement in the patient's symptoms was noted (Fig. 2).
Fig. 2.

(A, B) Renal angiogram upon admission showing bilateral renal artery clots. (C, D) Repeat angiogram in the following day showing resolution of the clots.

(A, B) Renal angiogram upon admission showing bilateral renal artery clots. (C, D) Repeat angiogram in the following day showing resolution of the clots. To search for the source of emboli, US LE venous Duplex was performed and revealed right popliteal vein nonocclusive thrombosis. Also, to rule out paradoxical thrombus with PE and arterial thrombosis, TEE was done, which showed small PFO with predominantly left to right flow, negative bubble study and no pulmonary hypertension. The patient was discharged to home on DOAC therapy with outpatient follow-up, and a full hypercoagulability workup was sent, which came back unremarkable.

Discussion

Pulmonary embolism (PE) is one of the common causes of cardiovascular mortality [1]. The clinical presentation of PE is variable, ranging from asymptomatic and mild to severe and critical disease. Patients with PE present with nonspecific symptoms and signs such as dyspnea, chest pain, tachycardia, hypoxemia, and even shock [2]. Based on hemodynamic stability, cardiac biomarkers and RV strain, pulmonary embolisms are classified into low risk, intermediate (submassive), and high risk (massive) groups, while the intermediate (submassive) group is further subdivided into intermediate-low risk and intermediate-high PEs [3]. The submassive PE group includes hemodynamically stable patients with significant RV strain and/or cardiac injury [4]. This group accounts for 20%-25% of all pulmonary embolisms, and these patients are at high risk of progression to hemodynamic instability [5]. Since our patient was hemodynamically stable with significant RV strain and elevated cardiac biomarkers, he was diagnosed with submassive PE. Treatment of submassive PE targets the reduction of RV afterload and decreases RV strain. Endovascular therapy with CDT and mechanical thrombectomy has shown great success in treating submassive PE, in the last decade [6]. Catheter-directed intervention with directed thrombolysis or mechanical thrombectomy is increasingly used. It is assumed that it confers a lower risk of bleeding than systemic thrombolysis, and it has more efficacy than anticoagulation alone with low rates of procedural complications [7]. CDT involves the infusion of a thrombolytic agent intravascularly directly into the pulmonary artery adjacent to the clot burden through a percutaneous transcatheter. It rapidly decreases pulmonary artery pressures, reducing the right ventricle strain [8]. The current guidelines recommend using catheter-directed lytics in patients with intermediate-high-risk PE and relative contraindications to thrombolytic therapy or patients who failed or have absolute contraindications to thrombolytic therapy [9]. In our case, we pursued the CDT for PE due to the significant risks of bleeding with systemic thrombolysis; however, the presence of renal artery clots was an additional challenge. The renal angiogram showed adequate perfusion to both kidneys, so we decided to administer localized tPA for PE and then reevaluate the bilateral renal artery thrombi later without performing an urgent renal artery intervention. Mechanical thrombectomy and intra-arterial thrombolysis have been used to treat renal artery thrombosis [10]. The first case treated with intra-arterial thrombolysis was reported in 1981 [11]. We were planning to either use an extraction device for aspiration or administer localized tPA for the renal clots if they were not dissolved by the following day. Fortunately, the repeat angiogram showed resolution of all the thrombi in the renal arteries, and no further intervention was needed. As of today, no trials with enough power have been performed to evaluate the mortality benefits of this endovascular catheter-directed intervention for submassive PE or renal artery thrombosis; therefore, treatment decisions are still affected by the location of the thrombus, operator experience, and individual risk of bleeding [12]. More randomized trials with enough power are needed before CDT can be routinely used to treat submassive pulmonary embolism and/or renal artery clots.

Conclusion

CDT has been increasingly used to treat submassive PE as it is assumed to be safer than systemic thrombolysis with uncommon complications. Currently, treatment decisions are affected by the individual risk of bleeding, thrombus location, and operator experience. Aspiration devices can also be considered an alternative therapy for retrieving renal artery clots. More research is needed to prove the efficacy and safety of this approach.

Patient consent

As this is a case report, informed consent for publication has been obtained from the patient.
  11 in total

1.  Mechanical Thrombectomy in Pulmonary Embolism: Ready for Prime Time?

Authors:  Kush R Desai
Journal:  JACC Cardiovasc Interv       Date:  2021-01-13       Impact factor: 11.195

Review 2.  Submassive pulmonary embolism.

Authors:  Laurence W Busse; Jason S Vourlekis
Journal:  Crit Care Clin       Date:  2014-07       Impact factor: 3.598

3.  2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism.

Authors:  Stavros V Konstantinides; Adam Torbicki; Giancarlo Agnelli; Nicolas Danchin; David Fitzmaurice; Nazzareno Galiè; J Simon R Gibbs; Menno V Huisman; Marc Humbert; Nils Kucher; Irene Lang; Mareike Lankeit; John Lekakis; Christoph Maack; Eckhard Mayer; Nicolas Meneveau; Arnaud Perrier; Piotr Pruszczyk; Lars H Rasmussen; Thomas H Schindler; Pavel Svitil; Anton Vonk Noordegraaf; Jose Luis Zamorano; Maurizio Zompatori
Journal:  Eur Heart J       Date:  2014-08-29       Impact factor: 29.983

4.  Renal artery embolism: therapy with intra-arterial streptokinase infusion.

Authors:  C P Fischer; J W Konnak; K J Cho; F E Eckhauser; J C Stanley
Journal:  J Urol       Date:  1981-03       Impact factor: 7.450

5.  Percutaneous mechanical thrombectomy and pharmacologic thrombolysis for renal artery embolism: case report and review of endovascular treatment.

Authors:  Tze-Woei Tan; W Todd Bohannon; Mark A Mattos; Kim J Hodgson; Alik Farber
Journal:  Int J Angiol       Date:  2011-06

Review 6.  Rationale for catheter directed therapy in pulmonary embolism.

Authors:  Sailen G Naidu; Martha-Gracia Knuttinen; J Scott Kriegshauser; William G Eversman; Rahmi Oklu
Journal:  Cardiovasc Diagn Ther       Date:  2017-12

Review 7.  Invasive Strategies for the Treatment of Pulmonary Embolism. Where Are We in 2020?

Authors:  Miguel A Maturana; Michael P Seitz; Issa Pour-Ghaz; Uzoma N Ibebuogu; Rami N Khouzam
Journal:  Curr Probl Cardiol       Date:  2020-07-22       Impact factor: 5.200

8.  Clinical characteristics of patients with acute pulmonary embolism: data from PIOPED II.

Authors:  Paul D Stein; Afzal Beemath; Fadi Matta; John G Weg; Roger D Yusen; Charles A Hales; Russell D Hull; Kenneth V Leeper; H Dirk Sostman; Victor F Tapson; John D Buckley; Alexander Gottschalk; Lawrence R Goodman; Thomas W Wakefied; Pamela K Woodard
Journal:  Am J Med       Date:  2007-10       Impact factor: 4.965

9.  Diagnosis, Treatment and Follow Up of Acute Pulmonary Embolism: Consensus Practice from the PERT Consortium.

Authors:  Belinda Rivera-Lebron; Michael McDaniel; Kamran Ahrar; Abdulah Alrifai; David M Dudzinski; Christina Fanola; Danielle Blais; David Janicke; Roman Melamed; Kerry Mohrien; Elizabeth Rozycki; Charles B Ross; Andrew J Klein; Parth Rali; Nicholas R Teman; Leoara Yarboro; Eugene Ichinose; Aditya M Sharma; Jason A Bartos; Mahir Elder; Brent Keeling; Harold Palevsky; Soophia Naydenov; Parijat Sen; Nancy Amoroso; Josanna M Rodriguez-Lopez; George A Davis; Rachel Rosovsky; Kenneth Rosenfield; Christopher Kabrhel; James Horowitz; Jay S Giri; Victor Tapson; Richard Channick
Journal:  Clin Appl Thromb Hemost       Date:  2019 Jan-Dec       Impact factor: 2.389

10.  Time Trends in Pulmonary Embolism Mortality Rates in the United States, 1999 to 2018.

Authors:  Karlyn A Martin; Rebecca Molsberry; Michael J Cuttica; Kush R Desai; Daniel R Schimmel; Sadiya S Khan
Journal:  J Am Heart Assoc       Date:  2020-08-17       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.